[
  {
    "ts": null,
    "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
    "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=42efe049fd0570e714508ece3f6c6d5d2f7583cbc169de2f6e97342e6421a0dd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752167280,
      "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
      "id": 135989071,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=42efe049fd0570e714508ece3f6c6d5d2f7583cbc169de2f6e97342e6421a0dd"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $208.00. The company reported a 6% year-over-year growth in total revenue to $2.4 billion, while […]",
    "url": "https://finnhub.io/api/news?id=929f97c6bdcdd4fa431bb3d4412d41a8d45eed1de58551371d292a056251e790",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752160454,
      "headline": "RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT",
      "id": 135856727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $208.00. The company reported a 6% year-over-year growth in total revenue to $2.4 billion, while […]",
      "url": "https://finnhub.io/api/news?id=929f97c6bdcdd4fa431bb3d4412d41a8d45eed1de58551371d292a056251e790"
    }
  },
  {
    "ts": null,
    "headline": "Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress",
    "summary": "– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK)",
    "url": "https://finnhub.io/api/news?id=e78da2ce431b58e52329cf08a3b757f34971eafabfed5f3792a78b5720949952",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752145200,
      "headline": "Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress",
      "id": 135851445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK)",
      "url": "https://finnhub.io/api/news?id=e78da2ce431b58e52329cf08a3b757f34971eafabfed5f3792a78b5720949952"
    }
  },
  {
    "ts": null,
    "headline": "Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress",
    "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., July 10, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a bro",
    "url": "https://finnhub.io/api/news?id=4d994501e0e688984803a3cb1ba3bd12f30c5e488b78383ffe1343a5946ff519",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752145200,
      "headline": "Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress",
      "id": 135851444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., July 10, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a bro",
      "url": "https://finnhub.io/api/news?id=4d994501e0e688984803a3cb1ba3bd12f30c5e488b78383ffe1343a5946ff519"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT",
    "summary": "Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Barclays upgraded the company’s stock to “Overweight” from “Equal Weight” with a price objective of $57, an increase from the prior target of $51, ahead of the Tryngolza Phase 3 CORE/CORE2 data in severe hypertriglyceridemia, as reported by The […]",
    "url": "https://finnhub.io/api/news?id=2a9deb6742e45552bbbbddc4dc2a16a7bf439ff9790bdabce9967547b739fbfa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752122393,
      "headline": "Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT",
      "id": 135856730,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Barclays upgraded the company’s stock to “Overweight” from “Equal Weight” with a price objective of $57, an increase from the prior target of $51, ahead of the Tryngolza Phase 3 CORE/CORE2 data in severe hypertriglyceridemia, as reported by The […]",
      "url": "https://finnhub.io/api/news?id=2a9deb6742e45552bbbbddc4dc2a16a7bf439ff9790bdabce9967547b739fbfa"
    }
  }
]